1
|
Bojja S, Javed N, Aziz MA, Fortuzi K, Khaja M. Metastatic Prostate Cancer With Reticular Micronodular Opacities of Lung: A Case Report. Cureus 2023; 15:e42698. [PMID: 37654947 PMCID: PMC10465714 DOI: 10.7759/cureus.42698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/30/2023] [Indexed: 09/02/2023] Open
Abstract
Prostate cancer, a common malignancy in males, can metastasize to various sites such as the bone, brain, liver, and less commonly, the lung. Detecting pulmonary metastases presents both diagnostic and therapeutic difficulties. Identifying patients with this condition is crucial for gaining a deeper comprehension of the disease's pathogenesis. In this report, we describe the case of a 64-year-old African American male who exhibited elevated prostate antigen levels and was found to have unique reticular Micronodular opacities in the lungs caused by prostate cancer.
Collapse
Affiliation(s)
- Srikaran Bojja
- Internal Medicine, BronxCare Health System, Icahn School of Medicine at Mount Sinai, New York City, USA
| | - Nismat Javed
- Internal Medicine, BronxCare Health System, Icahn School of Medicine at Mount Sinai, New York City, USA
| | - Muhammad Ali Aziz
- Internal Medicine, BronxCare Health System, Icahn School of Medicine at Mount Sinai, New York City, USA
| | - Ked Fortuzi
- Pulmonology, BronxCare Health System, Icahn School of Medicine at Mount Sinai, New York City, USA
| | - Misbahuddin Khaja
- Pulmonology and Critical Care, BronxCare Health System, Icahn School of Medicine at Mount Sinai, New York City, USA
| |
Collapse
|
2
|
Lev A, Lulla AR, Ross BC, Ralff MD, Makhov PB, Dicker DT, El-Deiry WS. ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer. Mol Cancer Res 2018; 16:754-766. [PMID: 29588330 DOI: 10.1158/1541-7786.mcr-17-0614] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2017] [Revised: 01/11/2018] [Accepted: 01/23/2018] [Indexed: 01/15/2023]
Abstract
Androgen receptor (AR) signaling plays a key role in prostate cancer progression, and androgen deprivation therapy (ADT) is a mainstay clinical treatment regimen for patients with advanced disease. Unfortunately, most prostate cancers eventually become androgen-independent and resistant to ADT with patients progressing to metastatic castration-resistant prostate cancer (mCRPC). Constitutively activated AR variants (AR-V) have emerged as mediators of resistance to AR-targeted therapy and the progression of mCRPC, and they represent an important therapeutic target. Out of at least 15 AR-Vs described thus far, AR-V7 is the most abundant, and its expression correlates with ADT resistance. ONC201/TIC10 is the founding member of the imipridone class of small molecules and has shown anticancer activity in a broad range of tumor types. ONC201 is currently being tested in phase I/II clinical trials for advanced solid tumors, including mCRPC, and hematologic malignancies. There has been promising activity observed in patients in early clinical testing. This study demonstrates preclinical single-agent efficacy of ONC201 using in vitro and in vivo models of prostate cancer. ONC201 has potent antiproliferative and proapoptotic effects in both castration-resistant and -sensitive prostate cancer cells. Furthermore, the data demonstrate that ONC201 downregulates the expression of key drivers of prostate cancer such as AR-V7 and downstream target genes including the clinically used biomarker PSA (KLK3). Finally, the data also provide a preclinical rationale for combination of ONC201 with approved therapeutics for prostate cancer such as enzalutamide, everolimus (mTOR inhibitor), or docetaxel.Implications: The preclinical efficacy of ONC201 as a single agent or in combination, in hormone-sensitive or castration-resistant prostate cancer, suggests the potential for immediate clinical translation. Mol Cancer Res; 16(5); 754-66. ©2018 AACR.
Collapse
Affiliation(s)
- Avital Lev
- Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Molecular Therapeutics Program, Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania
| | - Amriti R Lulla
- Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Molecular Therapeutics Program, Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania
| | - Brian C Ross
- Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Molecular Therapeutics Program, Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania
| | - Marie D Ralff
- Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Molecular Therapeutics Program, Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania
| | - Petr B Makhov
- Department of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania
| | - David T Dicker
- Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Molecular Therapeutics Program, Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania
| | - Wafik S El-Deiry
- Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Molecular Therapeutics Program, Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
| |
Collapse
|
3
|
Karzai FH, Apolo AB, Cao L, Madan RA, Adelberg DE, Parnes H, McLeod DG, Harold N, Peer C, Yu Y, Tomita Y, Lee MJ, Lee S, Trepel JB, Gulley JL, Figg WD, Dahut WL. A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer. BJU Int 2015; 116:546-55. [PMID: 25407442 DOI: 10.1111/bju.12986] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
OBJECTIVE TRC105 is a chimeric immunoglobulin G1 monoclonal antibody that binds endoglin (CD105). This phase I open-label study evaluated the safety, pharmacokinetics and pharmacodynamics of TRC105 in patients with metastatic castration-resistant prostate cancer (mCRPC). PATIENTS AND METHODS Patients with mCRPC received escalating doses of i.v. TRC105 until unacceptable toxicity or disease progression, up to a predetermined dose level, using a standard 3 + 3 phase I design. RESULTS A total of 20 patients were treated. The top dose level studied, 20 mg/kg every 2 weeks, was the maximum tolerated dose. Common adverse effects included infusion-related reaction (90%), low grade headache (67%), anaemia (48%), epistaxis (43%) and fever (43%). Ten patients had stable disease on study and eight patients had declines in prostate specific antigen (PSA). Significant plasma CD105 reduction was observed at the higher dose levels. In an exploratory analysis, vascular endothelial growth factor (VEGF) was increased after treatment with TRC105 and VEGF levels were associated with CD105 reduction. CONCLUSION TRC105 was tolerated at 20 mg/kg every other week with a safety profile distinct from that of VEGF inhibitors. A significant induction of plasma VEGF was associated with CD105 reduction, suggesting anti-angiogenic activity of TRC105. An exploratory analysis showed a tentative correlation between the reduction of CD105 and a decrease in PSA velocity, suggestive of potential activity of TRC105 in the patients with mCRPC. The data from this exploratory analysis suggest that rising VEGF level is a possible compensatory mechanism for TRC105-induced anti-angiogenic activity.
Collapse
Affiliation(s)
- Fatima H Karzai
- Medical Oncology Service, National Cancer Institute, Bethesda, MD, USA
| | - Andrea B Apolo
- Medical Oncology Service, National Cancer Institute, Bethesda, MD, USA
| | - Liang Cao
- Medical Oncology Service, National Cancer Institute, Bethesda, MD, USA
| | - Ravi A Madan
- Medical Oncology Service, National Cancer Institute, Bethesda, MD, USA
| | - David E Adelberg
- Medical Oncology Service, National Cancer Institute, Bethesda, MD, USA
| | - Howard Parnes
- Medical Oncology Service, National Cancer Institute, Bethesda, MD, USA
| | - David G McLeod
- Medical Oncology Service, National Cancer Institute, Bethesda, MD, USA
| | - Nancy Harold
- Medical Oncology Service, National Cancer Institute, Bethesda, MD, USA
| | - Cody Peer
- Medical Oncology Service, National Cancer Institute, Bethesda, MD, USA
| | - Yunkai Yu
- Medical Oncology Service, National Cancer Institute, Bethesda, MD, USA
| | - Yusuke Tomita
- Medical Oncology Service, National Cancer Institute, Bethesda, MD, USA
| | - Min-Jung Lee
- Medical Oncology Service, National Cancer Institute, Bethesda, MD, USA
| | - Sunmin Lee
- Medical Oncology Service, National Cancer Institute, Bethesda, MD, USA
| | - Jane B Trepel
- Medical Oncology Service, National Cancer Institute, Bethesda, MD, USA
| | - James L Gulley
- Medical Oncology Service, National Cancer Institute, Bethesda, MD, USA
| | - William D Figg
- Medical Oncology Service, National Cancer Institute, Bethesda, MD, USA
| | - William L Dahut
- Medical Oncology Service, National Cancer Institute, Bethesda, MD, USA
| |
Collapse
|
4
|
Tian X, He Y, Zhou J. Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance. Front Pharmacol 2015; 6:57. [PMID: 25852559 PMCID: PMC4371693 DOI: 10.3389/fphar.2015.00057] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2014] [Accepted: 03/05/2015] [Indexed: 12/30/2022] Open
Abstract
Androgen receptor (AR) plays a critical role in the development and progression of prostate cancer (PCa). Current clinically used antiandrogens such as flutamide, bicalutamide, and newly approved enzalutamide mainly target the hormone binding pocket (HBP) of AR. However, over time, drug resistance invariably develops and switches these antiandrogens from antagonist to agonist of the AR. Accumulated evidence indicates that AR mutation is an important cause for the drug resistance. This review will give an overview of the mutation based resistance of the current clinically used antiandrogens and the rational drug design to overcome the resistance, provides a promising strategy for the development of the new generation of antiandrogens targeting HBP.
Collapse
Affiliation(s)
- Xiaohong Tian
- Lady Davis Institute, Jewish General Hospital, Mcgill University Montreal, QC, Canada
| | - Yang He
- Immunology, Institute of Medicinal Biotechnology Chinese Academy of Medical Science Beijing, China
| | - Jinming Zhou
- Immunology, Institute of Medicinal Biotechnology Chinese Academy of Medical Science Beijing, China
| |
Collapse
|
5
|
Borrego-Diaz E, Powers BC, Azizov V, Lovell S, Reyes R, Chapman B, Tawfik O, McGregor D, Diaz FJ, Wang X, Veldhuizen PV. A potential regulatory loop between Lin28B:miR‑212 in androgen-independent prostate cancer. Int J Oncol 2014; 45:2421-9. [PMID: 25201220 PMCID: PMC4215582 DOI: 10.3892/ijo.2014.2647] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2014] [Accepted: 07/11/2014] [Indexed: 12/20/2022] Open
Abstract
Lin28 is a family of RNA binding proteins and microRNA regulators. Two members of this family have been identified: Lin28A and Lin28B, which are encoded by genes localized in different chromosomes but share a high degree of sequence identity. The role of Lin28B in androgen-independent prostate cancer (AIPC) is not well understood. Lin28B is expressed in all grades of prostatic carcinomas and prostate cancer cell lines, but not in normal prostate tissue. In this study we found that Lin28B co-localized in the nucleus and cytoplasm of the DU145 AIPC. The expression of Lin28B protein positively correlated with the expression of the c-Myc protein in the prostate cancer cell lines and silencing of Lin28B also correlated with a lower expression of the c-Myc protein, but not with the downregulation of c-Myc messenger RNA (mRNA) in the DU145 AIPC cells. We hypothesized that Lin28B regulates the expression of c-Myc protein by altering intermediate c-Myc suppressors. Therefore, a microRNA profile of DU145 cells was performed after Lin28B siRNA silencing. Nineteen microRNAs were upregulated and eleven microRNAs were downregulated. The most upregulated microRNAs were miR-212 and miR-2278. Prior reports have found that miR-212 is suppressed in prostate cancer. We then ran TargetScan software to find potential target mRNAs of miR-212 and miR-2278, and it predicted Lin28B mRNA as a potential target of miR-212, but not miR-2278. TargetScan also predicted that c-Myc mRNA is not a potential target of miR-212 or miR-2278. These observations suggest that Lin28B:miR-212 may work as a regulatory loop in androgen-independent prostate cancer. Furthermore, we report a predictive 2-fold symmetric model generated by the superposition of the Lin28A structure onto the I-TASSER model of Lin28B. This structural model of Lin28B suggests that it shows unique microRNA binding characteristics. Thus, if Lin28B were to bind miRNAs in a manner similar to Lin28A, conformational changes would be necessary to prevent steric clashes in the C-terminal and linker regions between the CSD and ZNF domains.
Collapse
Affiliation(s)
- Emma Borrego-Diaz
- Division of Hematology/Oncology, Department of Internal Medicine, University of Kansas Medical Center, Westwood, KS 66205, USA
| | - Benjamin C Powers
- Division of Hematology/Oncology, Department of Internal Medicine, University of Kansas Medical Center, Westwood, KS 66205, USA
| | - Vugar Azizov
- Division of Hematology/Oncology, Department of Internal Medicine, University of Kansas Medical Center, Westwood, KS 66205, USA
| | - Scott Lovell
- Protein Structure Laboratory, Del Shankel Structural Biology Center, University of Kansas, Main Campus, Lawrence, KS 66047, USA
| | - Ruben Reyes
- Division of Hematology/Oncology, Department of Internal Medicine, University of Kansas Medical Center, Westwood, KS 66205, USA
| | - Bradley Chapman
- Division of Hematology/Oncology, Department of Internal Medicine, University of Kansas Medical Center, Westwood, KS 66205, USA
| | - Ossama Tawfik
- University of Kansas Cancer Center, Kansas City, KS 66160, USA
| | - Douglas McGregor
- Veterans Administration Medical Center, Kansas City, MO 64128, USA
| | | | - Xinkun Wang
- Genomic Facility, University of Kansas, Main Campus, Lawrence, KS 66047, USA
| | - Peter Van Veldhuizen
- Division of Hematology/Oncology, Department of Internal Medicine, University of Kansas Medical Center, Westwood, KS 66205, USA
| |
Collapse
|